कंपनी का अवलोकन
Chemed Corporation operates within the Healthcare sector, specifically focusing on the Medical Care Facilities industry, by delivering essential hospice and palliative care services to patients across the United States. This business model relies on a comprehensive network comprising physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers to support end-of-life care needs. The company's scale is substantial, with a market capitalization of $5.71B and an annual revenue of $2.53B, supported by a workforce of 15,811 employees. These valuation and revenue figures indicate that Chemed Corporation holds a significant position as a major provider in the hospice industry, reflecting the steady demand for palliative care services and the company's established operational footprint.
वित्तीय स्वास्थ्य
The company generated revenue of $2.53B (TTM) with a net income of $265.24M and an EBITDA of $404.40M, revealing a cost structure where operating expenses consume a significant portion of top-line revenue. The free cash flow stands at $246.01M, which provides the organization with substantial financial flexibility to manage operational costs, invest in its service network, or pursue strategic initiatives without immediate reliance on external financing. Margin analysis shows a gross margin of 32.5%, an operating margin of 16.6%, and a profit margin of 10.5%, indicating that while the company maintains healthy profitability, the gap between gross and operating margins highlights substantial overhead costs associated with managing a large service network. On the balance sheet, Chemed holds $74.52M in cash against $143.76M in debt, resulting in a debt-to-equity ratio of 14.68%, suggesting a leveraged capital structure rather than a conservative, cash-heavy stance. The current ratio is 1.05, which indicates that the company's short-term liquid assets are just slightly above its current liabilities, pointing to a tight liquidity position that requires efficient working capital management. Return on Equity is reported at 25.3% while Return on Assets is 13.4%, metrics that reveal management is generating high returns on shareholders' equity but that asset utilization efficiency is moderate given the capital-intensive nature of healthcare services.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 21.32, whereas the forward P/E is 14.68, a significant difference that implies the market expects earnings to decline or grow at a rate that will lower the multiple in the coming periods. The price-to-book ratio stands at 5.47, indicating that the stock trades at a substantial premium over its book value, reflecting the value of its intangible assets, brand reputation, and network of healthcare providers. Alternative valuation metrics include a price-to-sales ratio of 2.26 and an EV/EBITDA of 13.47, which suggest the company is priced higher relative to its sales and enterprise value compared to some low-margin utility sectors but consistent with growth-oriented healthcare services. The stock's price range over the last year spans from a low of $365.21 to a high of $604.91, and without a specific current price provided in the facts, the trading position relative to this range cannot be precisely calculated, though the wide range suggests notable volatility. The beta value is 0.48, which means the stock's price volatility is significantly lower than the broader market, making it a less sensitive instrument to general market swings compared to large-cap technology or financial stocks.
Growth & Income
Revenue growth year-over-year is -0.1% while earnings growth year-over-year is -9.1%, indicating that earnings are contracting at a much faster rate than revenue, which implies rising costs or margin compression affecting profitability more severely than top-line volume. As a dividend payer, Chemed offers a dividend yield of 0.6% with a payout ratio of 12.0%, suggesting that the dividend payments are highly sustainable given that only a small fraction of earnings is distributed to shareholders. The low payout ratio allows the company to retain most of its earnings to fund operations and network expansion rather than prioritizing high dividend payments to investors. Overall, the growth and income profile is characterized by modest revenue stability coupled with recent earnings contraction and a conservative, low-yield dividend policy that prioritizes capital retention over shareholder income distribution.